A pooled analysis of four clinical trials evaluating delandistrogene moxeparvovec in young, ambulatory patients with Duchenne muscular dystrophy reported a manageable cardiac safety profile over up to five years of follow-up. The assessment supports durability of the safety signal across extended monitoring. The data were framed as pooled across predominantly early-stage cohorts, which may inform risk discussions for clinicians and families considering gene therapy participation and long-term follow-up requirements. While the analysis describes overall safety as manageable, the clinical context still requires attention to baseline risk factors and systematic cardiology monitoring, consistent with gene therapy practice norms.